<DOC>
	<DOCNO>NCT00003443</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness bryostatin 1 treat patient metastatic recurrent head neck cancer .</brief_summary>
	<brief_title>Bryostatin 1 Treating Patients With Metastatic Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate antitumor activity bryostatin 1 chemotherapy naive patient metastatic recurrent head neck squamous cell carcinoma , curable surgery radiation therapy . II . Evaluate safety toxicity bryostatin 1 administer prescribed schedule patient population . III . Assess cyclin dependent kinase 2 activity , protein kinase C activity , apoptosis measurement select patient tumor accessible biopsy follow bryostatin 1 therapy . OUTLINE : Patients receive bryostatin 1 IV 24 hour weekly three week follow one week rest . Treatment continue every 4 week absence unacceptable toxicity disease progression . Patients stable disease two course may continue treatment stop treatment discretion treat physician . PROJECTED ACCRUAL : There 14-25 patient accrue study 1-2 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic recurrent squamous cell carcinoma oral cavity , lip , hypopharynx , oropharynx , nasopharynx , paranasal sinus , nasal cavity , nostril , larynx curable surgery radiation therapy Must one measurable indicator lesion Bone metastasis , brain metastasis , elevate enzyme level lesion radionuclide scan acceptable sole parameter measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL Transaminases ( SGOT/SGPT ) less 2.5 time upper limit normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No unstable cardiac rhythm Other : No active infection require antibiotic No concurrent medical condition make participation study medically unsafe No prior malignancy last 2 year except basal squamous cell carcinoma skin , carcinoma situ cervix , metachronous/synchronous epidermoid/squamous cell cancer head neck Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : One prior chemotherapy regimen part locoregional treatment ( e.g. , induction/concomitant ) allow , either primary treatment therapy locoregional relapse , relapse occur 6 month later No prior chemotherapy Prior chemoprevention agent ( e.g. , cisretinoic acid vitamin analogue ) allow Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No prior radiotherapy 50 % bone marrowbearing bone Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>